Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of albuterol and methylprednisolone is used in respiratory conditions, particularly for treating asthma and COPD (Chronic Obstructive Pulmonary Disease). This combination leverages the bronchodilator effects of albuterol with the anti-inflammatory properties of methylprednisolone. Albuterol is a short-acting beta-2 adrenergic receptor agonist that relaxes bronchial smooth muscle, providing quick relief from bronchospasm[2]. It's 29 times more selective for beta-2 receptors than beta-1 receptors, giving it higher specificity for pulmonary receptors versus those in the heart[2]. Methylprednisolone is a corticosteroid that reduces inflammation in the airways. Research has shown that methylprednisolone increases sensitivity to beta-adrenergic agonists like albuterol within 48 hours of administration[3]. This synergistic effect makes the combination particularly effective for treating acute respiratory conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Albuterol + Methylprednisolone.